Alnylam Pharma (ALNY) Misses Q3 EPS by 7c
Get Alerts ALNY Hot Sheet
Price: $143.71 -0.06%
Revenue Growth %: +33.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +33.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.21), $0.07 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $13.7 million versus the consensus estimate of $9.14 million.
At September 30, 2016, Alnylam had cash, cash equivalents and marketable securities, and restricted investments of $1.19 billion, as compared to cash, cash equivalents and marketable securities of $1.28 billion at December 31, 2015.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
- SPS Commerce (SPSC) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!